01—Abstract
Summary
Summary of the 10-Q filed April 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (LH) reported first-quarter 2025 revenues of $3,345.1 milliona, up from $3,176.6 million a year earlier, with the filing attributing the increase to acquisitions, net of divestitures, of 3.7% and organic revenue growth of 2.1%, partly offset by unfavorable foreign currency translation of 0.5%.
Operating income rose to $326.0 millionb from $321.3 million, while net earnings attributable to Labcorp Holdings Inc. declined to $212.8 million from $228.0 million, and diluted EPS was $2.52 versus $2.69. Interest expense increased to $56.0 million from $46.9 million, reflecting higher average debt outstanding, and Other, net fell to a $(1.0) million expense from $20.0 million, primarily due to lower transition services fees charged to Fortrea. Liquidity was reshaped during the quarter.
Cash and cash equivalents fell to $369.4 millionc from $1,518.7 million at year-end 2024 after the company repaid $1,000.0 million of 3.60% senior notes due 2025 and invested $157.0 million in equity affiliates, including the SYNLAB minority interest. Operating cash flow improved to $18.5 million from a $(29.8) million outflow, which the filing attributes primarily to timing of working capital requirements. Long-term debt rose to $5,568.7 million, partly due to an increase in the accounts receivable facility balance to $525.0 million, and the company amended its AR facility to allow borrowings up to $700.0 million.
The company had $1,000.0 milliond of undrawn revolving credit facility capacity at quarter end. The filing also details ongoing legal matters, including the Ravgen patent case (with a jury damages award of $272.0 million from 2022 and subsequent orders), the AMCA data security multidistrict litigation, and a Texas Medicaid qui tam action. The company states it will vigorously defend these matters and that it does not believe they will have a material adverse effect on its financial statements, though the Ravgen matter's outcome is disclosed as uncertain pending appeal.
02—Key points
Key Highlights
- Revenues rose 5.3% to $3,345.1 million, with acquisitions contributing 3.7% and organic growth 2.1%; Dx revenues grew 6.0% to $2,629.6 million and BLS grew 1.5% to $721.3 million.
- Operating income increased to $326.0 million from $321.3 million, while net earnings attributable to Labcorp fell to $212.8 million from $228.0 million.
- Diluted EPS was $2.52 versus $2.69 in the prior-year quarter.
- Cash and cash equivalents dropped to $369.4 million after repaying $1,000.0 million of 3.60% senior notes due 2025.
- Operating cash flow turned positive at $18.5 million versus a $(29.8) million outflow a year earlier, primarily due to working capital timing.
- Accounts receivable securitization facility borrowing limit was increased from $300.0 million to $700.0 million, with $525.0 million outstanding at quarter end.
- Company acquired a 15% minority interest in SYNLAB (equity method, about $151.6 million) and agreed to acquire select BioReference oncology lab assets for up to $225.0 million, expected to close in the second half of 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Labcorp Holdings kept $0.06.
- Revenue$3.35B100.0%
- Cost of revenue−$2.40B71.7%
- Gross profit$948.0M28.3%
- Operating costs−$622.0M18.6%
- Operating income$326.0M9.7%
- Interest, other & tax−$113.2M3.4%
- Net income$212.8M6.4%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 29, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $3.35B$3.18B | +5.3% |
| Cost of Revenue | $2.40B$2.28B | +5.2% |
| Gross Profit | $948.00M$897.30M | +5.7% |
| SG&A Expenses | $546.00M$508.40M | +7.4% |
| Operating Income | $326.00M$321.30M | +1.5% |
| Interest Expense | $56.00M$46.90M | +19.4% |
| Net Income | $212.80M$228.00M | −6.7% |
| EPS (Basic) | $2.54$2.71 | −6.3% |
| EPS (Diluted) | $2.52$2.69 | −6.3% |
| Shares Outstanding (Basic) | 83.60M84.10M | −0.6% |
| Shares Outstanding (Diluted) | 84.30M84.70M | −0.5% |
05—Questions
Frequently Asked Questions
Why did net earnings attributable to Labcorp decline despite higher operating income?
Operating income rose to $326.0 million from $321.3 million, but interest expense increased to $56.0 million from $46.9 million, and Other, net swung to a $(1.0) million expense from $20.0 million, mainly because of lower transition services fees charged to Fortrea. Net earnings attributable to Labcorp Holdings Inc. were $212.8 million versus $228.0 million a year earlier.
How did the company fund the $1,000.0 million senior note repayment?
Cash on hand declined substantially, with cash and cash equivalents falling to $369.4 million from $1,518.7 million at year-end 2024. The company also received $225.0 million of loan proceeds under its accounts receivable securitization facility during the quarter, and it had $1,000.0 million of available borrowings under its revolving credit facility at March 31, 2025.
What drove revenue growth in the first quarter of 2025?
Total revenues increased 5.3% to $3,345.1 million. The filing attributes 3.7 percentage points to acquisitions, net of divestitures, and 2.1 percentage points to organic growth, partially offset by 0.5 percentage points of unfavorable foreign currency translation. Dx revenue growth of 6.0% was partly weather-impacted, and BLS organic growth was 2.6%.
What is the status of the Ravgen patent litigation?
A jury in 2022 found the company willfully infringed a Ravgen patent and awarded damages of $272.0 million. The court later awarded enhanced damages of $100.0 million and, in January 2025, supplemental damages of $2.6 million plus an ongoing royalty per test. The trial court denied the company's post-trial motions in January and February 2025, and the company states it strongly disagrees with the verdict and will vigorously defend the lawsuit through appeal.
What are the company's capital allocation plans?
The company paid $61.6 million in dividends during the quarter and declared a $0.72 per share dividend on April 10, 2025, totaling approximately $61.2 million, payable June 11, 2025. No shares were repurchased in the quarter, and $1,280.4 million remained under the Board's repurchase authorization, which has no expiration date. Capital expenditures were $126.0 million, or 3.8% of revenues, and the company expects similar spending levels for the rest of 2025.
06—Continue